Cincinnati Children’s opens faculty search for brain tumor research in CNS malignancies
Cincinnati Children’s Hospital Medical Center is recruiting a faculty scientist for brain tumor research, with appointments available at the assistant, associate, or full professor level. The position sits inside the Cancer and Blood Diseases Institute and is aimed at investigators focused on brain tumors and other central nervous system malignancies. The institution is looking for a laboratory scientist or physician-scientist who can build an independent research program that moves from fundamental discovery into therapeutic translation.
The emphasis is unusually specific. Candidates are being sought for work that does not stop at descriptive biology, but instead uses mechanistic studies to guide treatment strategies for tumors of the brain and CNS. Cellular and immune therapies, small-molecule therapeutics, and other innovative approaches are all within scope, provided they are grounded in rigorous tumor biology.
Translational programs are the core of the recruitment
The opening reflects a deliberate effort to deepen an integrated brain tumor research program across discovery science, disease modeling, therapeutic development, and clinical investigation. At a practical level, that means the new faculty member is expected to operate at the junction where laboratory findings can be turned into testable treatment concepts. Brain tumors remain biologically complex, and durable progress depends on understanding how tumor cells interact with their microenvironment, how they evade immune surveillance, and which pathways can be targeted without unacceptable toxicity to the developing nervous system.
The institute is positioning the hire within either the Division of Experimental Hematology and Cancer Biology or the Division of Oncology, depending on the candidate’s scientific and clinical profile. For a physician-scientist, that structure allows a laboratory program to remain closely connected to patient care and clinical questions. For a basic scientist, it places the work inside a setting built to move mechanistic insights toward therapy development.
One sentence captures the tone of the search: the institution wants biology that can be translated, not simply catalogued.
Infrastructure spans genomics, modeling, and cell therapy platforms
The research environment described for the position is expansive. Cincinnati Children’s cites access to genomics and single-cell technologies, proteomics and metabolomics, genome engineering, computational biology, human biospecimens, preclinical models, drug discovery resources, and cellular and immune therapy platforms. Those tools matter because brain tumor biology rarely yields to a single experimental lens. Heterogeneity across tumor cells, resistance pathways, and the surrounding immune and stromal compartments often requires paired molecular and functional approaches before a therapeutic target can be trusted.
The recruitment also points to collaborations beyond the cancer enterprise itself. Investigators can connect with colleagues in cancer biology, neuroscience, developmental biology, immunology, gene and cell therapy, and clinical oncology across Cincinnati Children’s, the University of Cincinnati College of Medicine, and the University of Cincinnati Cancer Center. For brain tumor research, that kind of cross-disciplinary environment is not a decorative extra. It is the infrastructure needed to connect tumor biology with neural development, immune regulation, and clinical trial design.
A faculty recruit entering such a program would not be working in isolation. The available platforms suggest an expectation that the successful candidate will bring an idea with enough depth to use the institution’s systems aggressively, from mechanism through preclinical validation.
Candidate expectations favor mechanistic depth and therapeutic ambition
The minimum credential is a PhD, MD, MD/PhD, or an equivalent doctoral degree, paired with an innovative research program centered on brain tumors or related CNS malignancies. Physician-scientists are explicitly welcomed if they intend to maintain an independent laboratory alongside clinical responsibilities. For junior faculty, the bar is an outstanding record of scientific accomplishment and clear potential to secure external funding. For more senior applicants, the search prioritizes established scholarship, extramural support, mentorship, and scientific leadership.
Priority is being given to investigators whose programs are deeply mechanistic and translational in orientation. The most attractive candidates will be those using biological insight to develop cellular or immune therapies or small-molecule therapeutics. This focus is clinically relevant because brain tumors demand treatment concepts that can address both disease biology and the barriers imposed by the central nervous system, including selective drug delivery, immune suppression, and the challenge of preserving neurologic function while attacking malignant tissue.
For a field where therapeutic advances often depend on carefully defined pathways rather than broad empiricism, the search is aimed at scientists who can bridge discovery, preclinical modeling, and therapy development. The institution is not asking for an incremental project. It is seeking a program with enough intellectual force to reshape how brain tumor biology is studied and how candidate treatments are built.
Cincinnati Children’s is using faculty hiring to expand cancer discovery
Cincinnati Children’s describes itself as one of the nation’s leading pediatric research institutions, with a research enterprise spanning basic discovery, translational science, and clinical investigation. Within that structure, the Cancer and Blood Diseases Institute integrates cancer biology, hematology, oncology, gene and cell therapy, and related disciplines to move fundamental discoveries toward improved therapies for children and young adults.
The appointment carries additional appeal for investigators who want a large institutional platform without sacrificing scientific independence. Faculty benefit from the resources of the Cincinnati Children’s Research Foundation and from partnerships with the University of Cincinnati College of Medicine and the University of Cincinnati Cancer Center. That combination gives the role reach across pediatric oncology, adult academic oncology, and a broader research ecosystem that can support collaboration, access to biospecimens, and clinical linkage.
Cincinnati itself is presented as an affordable metropolitan area with strong schools and a high quality of life for professionals and families. The job remains open on a rolling basis, and applicants are being asked to submit a CV, a 2- to 3-page research plan, and contact information for three references. Nathan Gohlke is listed as the faculty recruiter for additional information.
The most concrete implication of the search is institutional intent: Cincinnati Children’s is investing in a brain tumor program that can generate mechanistic insight and move candidate therapies toward the clinic. The unanswered question is which scientific niche the selected faculty member will fill, and how quickly that program can convert discovery into a pipeline with direct relevance for patients with CNS malignancies.